9-[[2-Benzyloxy-1-(benzyloxymethyl)-ethoxy]-methyl]-6-chloroguanine-d5

9-[[2-Benzyloxy-1-(benzyloxymethyl)-ethoxy]-methyl]-6-chloroguanine-d5 is a stable isotope-labeled analog of 9-[[2-Benzyloxy-1-(benzyloxymethyl)-ethoxy]-methyl]-6-chloroguanine, a guanine derivative that has been used for the treatment of acute myeloid leukemia (AML). This compound belongs to a class of chemotherapy agents known as purine analogs and is structurally similar to the natural purines present in DNA and RNA. The chemical structure of 9-[[2-Benzyloxy-1-(benzyloxymethyl)-ethoxy]-methyl]-6-chloroguanine-d5 includes five deuterium atoms, which replace five hydrogen atoms in the molecule. This isotope labeling enhances the sensitivity and specificity of analytical methods used to detect and quantify the compound in biological matrices, such as plasma or urine. The usage of 9-[[2-Benzyloxy-1-(benzyloxymethyl)-ethoxy]-methyl]-6-chloroguanine-d5 is mainly in research settings, where it can be used as an internal standard or reference compound in mass spectrometry-based assays. These assays can be used to measure the pharmacokinetics, metabolism, and bioavailability of the parent compound in preclinical and clinical studies. In conclusion, 9-[[2-Benzyloxy-1-(benzyloxymethyl)-ethoxy]-methyl]-6-chloroguanine-d5 is a labeled analog of a purine analog chemotherapy agent that is used mainly in research settings as an internal standard in mass spectrometry-based assays. Its chemical properties make it a useful tool for studying the pharmacokinetics, metabolism, and bioavailability of the parent compound in preclinical and clinical studies.